optimasi formula tablet salut enterik natrium diklofenak dengan bahan penyalut kollicoat 30 d

Clicks: 201
ID: 248546
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #26 of 31 articles by views in Cancer management and research

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Diclofenac sodium is an analgetic and antiinflammation drug and commonly used by oral administration. Because of it’s side effects that can cause stomach irritation, nausea and vomiting, it’s made in the form of enteric-coated. Enteric-coated formulations developed used organic solvent having toxicity and flammability risks. The aim of this study is to develop diclofenac sodium enteric-coated tablets with a water-based coating material. Coating material used is Kollicoat 30 D which is a derivative of acrylic polymer that can dispersed in water. Optimalization of the formula is done by the weight gain 4%, 6% and 8%. The result showed that enteric coated tablets used coating material with weight gain 8% gave the best result with all parameters meet the requirements of the test, there was no change in acid medium for 2 hours and stable released active ingredient
Reference Key
yunarto2015jurnaloptimasi Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Nanang Yunarto
Journal Cancer management and research
Year 2015
DOI
10.22435/jki.v4i2.4070.65-74
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.